A critical difference between our studies is that the previous study13 did not examine CSF biomarkers or any measure of ptau217, which is a sensitive marker for altered tau metabolism in Alzheimer’s disease.56 Another difference is that all the PRSs in Yang et al. 13 were constructed by excluding the APOE region SNPs. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.